The 2022 Award of the San Salvatore Foundation, Lugano, of CHF 50’000.00 Swiss Francs has been granted on June 14, 2023, in Lugano to
Prof. Margaret A. Shipp, MD
in recognition for her contribution to the understanding and treatment of large B-cell non-Hodgkin’s lymphomas.
Dr. Margaret Shipp received her Doctor of Medicine from Washington University School of Medicine and completed an internal medicine internship and residency at Barnes Hospital/Washington University. Thereafter, she completed a fellowship in Medical Oncology at DFCI and subsequently joined the faculty.
Dr. Shipp is currently the Chief of the Division of Hematologic Neoplasia at Dana-Farber Cancer Institute of Boston and a Professor of Medicine at Harvard Medical School. Her clinical and laboratory research focuses on the clinical and molecular heterogeneity of the large B-cell lymphomas (LBCLs) and Hodgkin lymphoma. Dr. Shipp coordinated the development of the International Prognostic Index which is used worldwide to individualize treatment approaches to LBCLs and many other lymphoid malignancies. More recently, she has led efforts to define molecular signatures of LBCLs and Hodgkin lymphomas, identify biologically distinct subsets of these diseases, and characterize associated rational treatment targets including modulators of the host anti-tumor immune response.
Dr. Shipp previously served on the Scientific Advisory Committee of the International Conference on Malignant Lymphoma and gave the first Gianni Bonadonna Memorial Lecture here in Lugano. Among others, she is member of the American Society for Clinical Investigation, the Association of American Physicians and the National Academy of Medicine and a Fellow of the American Association of Cancer Research Academy.
Dr. Shipp has authored or co-authored close to 200 publications with highest citation for the clinical publication “A Predictive Model for Aggressive Non-Hodgkin's Lymphoma” published in the New England Journal of Medicine in 1993 - which was the end result of a project initiated at a closed workshop of International Congress of Malignant Lymphoma - and the translational research publication “Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning” in Nature Medicine in 2002.
Dr. Shipp has received multiple awards, including recently the 2021 Ernest Beutler Lecture and Prize, and was elected for the 2022 class of Fellows of the American Association for Cancer Research. The San Salvatore Foundation, with its base in Lugano, Switzerland, was created in 1979 by Carlo Pernsch, a well-known banker, and his wife Célestine with the purpose of promoting and rewarding medical and scientific research in the area of antitumor therapies.
For over 44 years the San Salvatore Foundation has recognized with its awards numerous scientists who have contributed in a substantial manner to the scientific research on new approaches to antitumor therapeutics and has provided grants for scientific projects for the cure of malignant diseases.